ibrutinib to to be made available via cancer drugs fund after two trials
trials , in 28 british hospitals , showed it to be extremely effective in treating mantle cell lymphoma and chronic lymphocytic leukaemia
for now , ibrutinib ( which costs up to Â£ 74,000 a year ) will be prescribed only to patients whose disease does n't respond to chemotherapy